U.S. markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
80.70-1.21 (-1.48%)
At close: 1:00PM EST
81.08 +0.38 (+0.47%)
After hours: 04:43PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close81.91
Bid80.70 x 900
Ask81.08 x 800
Day's Range80.53 - 81.23
52 Week Range80.53 - 98.52
Avg. Volume2,122,590
Market Cap180.533B
Beta (5Y Monthly)0.53
PE Ratio (TTM)18.64
EPS (TTM)4.33
Earnings DateN/A
Forward Dividend & Yield3.20 (3.96%)
Ex-Dividend DateMar 04, 2021
1y Target Est104.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novartis AG
    Analyst Report: Novartis AGNovartis is a pharmaceutical company based in Switzerland. Its key divisions are Innovative Medicines (primary care and specialty drugs) and Sandoz generic pharmaceuticals. The company employs 110,000 people.
    Fair Value
    Economic Moat
    16 days agoArgus Research
View more
  • Reuters

    Roche shareholders approve deal to buy Novartis's $20.7 billion stake

    Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said. Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades. Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.

  • Motley Fool

    3 Pharma Stocks That Are Too Cheap to Ignore

    Here's why they think Bristol Myers Squibb (NYSE: BMY), Novartis (NYSE: NVS), and Viatris (NASDAQ: VTRS) are too cheap to ignore. Prosper Junior Bakiny (Bristol Myers Squibb): Investors are sometimes wary of undervalued companies.

  • Zacks

    Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST

    The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.